2.1
Vamorolone (Agamree, Santhera) is indicated for 'the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older'.
2 Information about vamorolone
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for vamorolone.
Price
2.3
The anticipated list price of vamorolone is £4,585.87 per 100 ml of a 40 mg/ml oral suspension (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes vamorolone available to the NHS with a discount. The size of the discount is commercial in confidence.